Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in rheumatoid arthritis: randomized controlled trial.
Linda T BetzGitta A JacobJohannes KnitzaMichaela KöhmFrank BehrensPublished in: Npj mental health research (2024)
Cognitive behavioral therapy improves psychosocial outcomes in rheumatoid arthritis (RA), but access is limited. We conducted a randomized controlled trial to evaluate the efficacy of a cognitive-behavioral digital therapeutic, reclarit, on psychosocial outcomes in adult RA patients with impaired health-related quality of life. Participants were randomized to reclarit plus treatment as usual (TAU) or TAU plus educational and informational material (active control). The primary outcome was SF-36 mental (MCS) and physical (PCS) component summary scores at 3 months, with additional assessments at 6 months. reclarit significantly improved SF-36 MCS scores compared to control (mean difference 3.3 [95% CI 0.7, 5.9]; p = 0.014), with high user satisfaction and sustained improvements at 6 months. Depression, anxiety, fatigue, and social/work functioning also improved significantly, while SF-36 PCS, pain, and disability scores did not differ. In conclusion, reclarit offers immediate, effective, evidence-based and personalized psychological support for RA patients.
Keyphrases
- rheumatoid arthritis
- mental health
- disease activity
- randomized controlled trial
- sleep quality
- ankylosing spondylitis
- end stage renal disease
- interstitial lung disease
- healthcare
- chronic pain
- ejection fraction
- newly diagnosed
- systemic lupus erythematosus
- physical activity
- depressive symptoms
- multiple sclerosis
- double blind
- peritoneal dialysis
- chronic kidney disease
- pain management
- prognostic factors
- study protocol
- type diabetes
- neuropathic pain
- metabolic syndrome
- open label
- systematic review
- adipose tissue
- clinical trial
- phase iii
- young adults
- childhood cancer